Analysts from H.C. Wainwright and J.P. Morgan raised their price targets for Cogent Biosciences.

COGT · Cogent Biosciences

The AI's read

These are opinions about Cogent, not new results from its drug programs or a change in its plans. Both firms kept positive ratings, but their target changes point in different directions. The report gives no new company results, so it does not support a change in Cogent's outlook.